The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Present issues in treating patients with relapsed/refractory CLL
Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from St James’s University Hospital Leeds, Leeds, UK, talks to us about managing the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and the clinical issues observed in patients failing treatment with B-cell receptor inhibitors. Here at EHA 2017, Prof. Hillmen and his team presented a number of cases on how physicians could manage the toxicities and progressions in CLL patients treated with novel therapies. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
